The dynamic nature of type 1 cannabinoid receptor CB1 transcription

British Journal of Pharmacology

Volumn 167, Issue 8, 2012, Pages 1583-1595

  Laprairie, R B ^a   Kelly, M E M ^a   Denovan Wright, E M ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

cannabinoids; development; Huntington's disease; inflammation; mRNA; obesity; Parkinson's disease; schizophrenia; type 1 cannabinoid receptor (CB1)

Indexed keywords

ALCOHOL; CANNABINOID; CANNABINOID 1 RECEPTOR; ESTRADIOL; GEMCITABINE; INSULIN; MESSENGER RNA; METHAMPHETAMINE; RETINOIC ACID;

5' UNTRANSLATED REGION; BREAST CANCER; CANNABINOID 1 RECEPTOR GENE; COLORECTAL CANCER; COLORECTAL CARCINOMA; DEVELOPMENTAL STAGE; DIABETES MELLITUS; DISEASE PREDISPOSITION; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; HUMAN; HUNTINGTON CHOREA; INFLAMMATION; LYMPHOMA; NONHUMAN; OBESITY; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; GENE EXPRESSION; HUMANS; RECEPTOR, CANNABINOID, CB1; RNA, MESSENGER;

EID: 84870494685     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2012.02175.x     Document Type: Review

References (89)

1. Ahn KH, Mahmoud MM, Kendall DA, (2012). Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation. J Biol Chem 287: 12070-12082.
2. Amaya F, Shimosato G, Kawasaki Y, Hashimoto S, Tanaka Y, Ji RR, et al,. (2006). Induction of CB1 cannabinoid receptor by inflammation in primary afferent neurons facilitates antihyperalgesic effect of peripheral CB1 agonist. Pain 124: 175-183.
3. Atwood BK, Mackie K, (2010). CB2: a cannabinoid receptor with an identity crisis. Br J Pharmacol 160: 467-479.
4. Atwood BK, Straiker A, Mackie K, (2012). CB2: therapeutic target-in-waiting. Prog Neuropsychopharmacol 38: 16-20.
5. Barbier E, Pierrefiche O, Vaudry D, Vaudry H, Daoust M, Naassila M, (2008). Long-term alterations in vulnerability to addiction to drugs of abuse in brain gene expression after early life ethanol exposure. Neuropharmacology 55: 1199-2211.
6. Basavarajappa B, Nixon R, Arancio O, (2009). Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. Mini Rev Med Chem 9: 448-462.
7. Benyamina A, Kebir O, Blecha L, Reynaud M, Krebs MO, (2011). CNR1 gene polymorphisms in addictive disorders: a systematic review and a meta-analysis. Addict Biol 16: 12-16.
8. 18fluoro-deoxyglucose positron emission tomography study. Diabetes 51: 3384-3390.
9. Blázquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, et al,. (2011). Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington's disease. Brain 134: 119-136.
10. Borner C, Holt V, Kraus J, (2007a). Activation of human T cells induces upregulation of cannabinoid type 1 transcription. Neuroimmunomodulation 14: 281-286.
11. Borner C, Holt V, Kraus J, (2007b). Transcriptional regulation of the cannabinoid receptor type 1 gene in T cells by cannabinoids. J Leukoc Biol 81: 336-343.
12. Borner C, Bedini A, Holt V, Kraus J, (2008). Analysis of promoter regions regulating basal and interleukin-4 inducible expression of the human CB1 receptor gene in T lymphocytes. Mol Pharmacol 73: 1013-1019.
13. Bortolato M, Frau R, Bini V, Luesu W, Loriga R, Collu M, et al,. (2010). Methamphetamine neurotoxicity increase brain expression and alters behavioural functions of CB1 cannabinoid receptors. J Psychiatr Res 44: 944-955.
14. Cacciola G, Chioccarelli T, Mackie K, Meccariello R, Ledent C, Fasano S, et al,. (2008). Expression of type-1 cannabinoid receptor during rat postnatal testicular development: possible involvement in adult leydig cell differentiation. Biol Reprod 79: 758-765.
15. Caffarel MM, Sarrio D, Palacios J, Guzman M, Sanchez C, (2006). Delta-9- tetrahydrocannabinol inhibits cell cycle progression in human breast cancer cells through Cdc2 regulation. Cancer Res 66: 6615-6621.
16. Caspi A, Moffitt TE, Cannon M, McClay J, Murray R, Harrington HL, et al,. (2005). Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-o-methyltrasnferase gene: longitudinal evidence of a gene x environment interaction. Biol Psychiatry 57: 1117-1127.
17. Corchero J, Romero J, Berrendero F, Fernandez-Ruiz J, Ramos JA, Fuentes JA, et al,. (1999). Time-dependent differences of repeated administration with Delta9-tetrahydrocannabinol in proenkephalin and cannabinoid receptor gene expression and G-protein activation by mu-opiod and CB1-cannabinoid receptors in the caudate-putamen. Brain Res Mol Brain Res 67: 148-157.
18. Cottone E, Guastalla A, Mackie K, Franzoni MF, (2008). Endocannabinoids affect the reproductive functions in teleosts and amphibians. Mol Cell Endocrinol 286: S41-S45.
19. Cravatt BF, Giang DK, Mayfield SP, Boger DL, Lerner RA, Gilula NB, (1996). Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature 384: 83-87.
20. Denovan-Wright EM, Robertson HA, (2000). Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex, and hippocampus of transgenic Huntington's disease mice. Neuroscience 98: 705-713.
21. Di Marzo V, Fontana A, Cadas H, Schinelli S, Cimino G, Schwartz JC, et al,. (1994). Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature 372: 686-691.
22. Diaz-Asensio C, Setien R, Echevarna E, Casis L, Casis E, Garrido A, et al,. (2008). Type 1 diabetes alters brain cannabinoid receptor expression and phosphorylation status in rats. Horm Metab Res 40: 454-458.
23. Eggan SM, Melchitsky DS, Sesack SR, Fish KN, Lewis DA, (2010). Relationship of cannabinoid CB1 receptor and cholecystokinin immunoreactivity in monkey dorsolateral prefrontal cortex. Neuroscience 169: 1651-1661.
24. El Khoury MA, Gorgievski V, Moutsimilli L, Giros B, Tzavara ET, (2012). Interactions between the cannabinoid and dopaminergic systems: evidence from animal studies. Prog Neuropsychopharmacol Biol Psychiatry 38: 56-60.
25. Fernandez-Ruiz J, Gomez M, Hernandez M, de Miguel R, Ramos JA, (2004). Cannabinoids and gene expression during brain development. Neurotox Res 6: 389-401.
26. Fitzgerald ML, Chan J, Mackie K, Lupica CR, Pickel VM, (2012). Altered dendritic distribution of dopamine D2 receptors and reduction in mitochondrial number in parvalbumin-containing interneurons in medial prefrontal cortex of cannabinoid-1 (CB1) receptor knockout mice. J Comp Neurol DOI: 10.1002/cne.23141. E-pub ahead of print.
27. Gafni J, Ellerby LM, (2002). Calpain activation in Huntington's disease. J Neurosci 22: 4842-4849.
28. Garcia-Arencibia M, Garcia C, Kurz A, Rodriguez-Navarro JA, Gispert-Sachez S, Mena MA, et al,. (2009). Cannabinoid CB1 receptors are early downregulated followed by a further upregulation in the basal ganglia of mice with deletion of specific park genes. J Neural Transm Suppl 73: 269-275.
29. Gene Expression Nervous System Atlas (GENSAT) Project (2010). Gene name: cannabinoid receptor 1 (brain). NINDS Contracts N01NS02331 & HHSN271200723015 to The Rockefeller University (New York, NY). Available at: http://www.gensat.org/GeneProgressTracker.jsp?gensatGeneID=397.
30. Gustafsson K, Wang X, Severa D, Eriksson M, Kimby E, Merup M, et al,. (2008). Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. Int J Cancer 123: 1025-1033.
31. Gutierrez T, Farthing JN, Zvonok AM, Makriyannis A, Hohmann AG, (2006). Activation of peripheral CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol 150: 153-163.
32. Heng L, Beverley JA, Steiner H, Tseng KY, (2011). Differential developmental trajectories for CB1 cannabinoid receptor expression in limbic/associative and sensorimotor cortical areas. Synapse 65: 278-286.
33. Hill MN, Hillard CJ, McEwen BS, (2011). Alterations in corticolimbic dendritic morphology and emotional behaviour in cannabinoid CB1 receptor-deficient mice parallel the effects of chronic stress. Cereb Cortex 21: 2056-2064.
34. Howlett AC, Barth F, Bonner TI, Cabral G, Casellas P, Devane WA, et al,. (2002). International Union of Pharmacology. XXVII. Classification of Cannabinoid Receptors. Pharmacol Rev 54: 161-202.
35. Hudson BD, Hebert TE, Kelly ME, (2010). Physical and functional interaction between CB1 cannabinoid receptors and beta2-adrenoceptors. Br J Pharmacol 160: 627-642.
36. Hurley MJ, Mash DC, Jenner P, (2003). Expression of cannabinoid CB1 receptor mRNA in basal ganglia of normal and parkinsonian human brain. J Neural Transm 110: 1279-1288.
37. Kalifa S, Polston EK, Allard JS, Manaye KF, (2011). Distribution patterns of cannabinoid CB1 receptors in the hippocampus of APPswe/PS1ÎE9 double transgenic mice. Brain Res 1376: 94-100.
38. Karvela A, Rojas-Gil AP, Samkinidou E, Papadaki H, Pappa A, Georgiou G, et al,. (2010). Endocannabinoid (EC) receptor, CB1, and EC enzymes' expression in primary adipocyte cultures of lean and obese pre-pubertal children in relation to adiponectin and insulin. J Pediatr Endocrinol Metab 23: 1011-1024.
39. Kempf K, Hector J, Strate T, Schwartzloh B, Rose B, Herder C, et al,. (2007). Immune-mediated activation of the endocannabinoid system in visceral adipose tissue in obesity. Horm Metab Res 39: 596-600.
40. Kim J, Alger BE, (2010). Reduction in endocannabinoid tone is a homeostatic mechanism for specific inhibitory synapses. Nat Neurosci 13: 592-600.
41. Larrinaga G, Sanz B, Perez I, Blanco L, Candenas ML, Pinto FM, et al,. (2010a). Cannabinoid CB1 receptor is downregulated in clear cell renal cell carcinoma. J Histochem Cytochem 58: 1129-1134.
42. Larrinaga G, Varona A, Perez I, Sanz B, Ugalde A, Candenas ML, et al,. (2010b). Expression of cannabinoid receptors in human kidney. Histol Histopathol 25: 1133-1138.
43. Lee JH, Agacinski G, Williams JH, Wilcock GK, Esiri MM, Francis PT, et al,. (2010). Intact cannabinoid CB1 receptors in Alzheimer's disease cortex. Neurochem Int 57: 985-989.
44. McCaw EA, Hu H, Gomez GT, Hebb AL, Kelly ME, Denovan-Wright EM, (2004). Structure, expression, and regulation of the cannabinoid receptor gene (CB1) in Huntington's disease transgenic mice. Eur J Biochem 271: 4909-4920.
45. Malfitano AM, Laezza C, Galgani M, Matarese G, D'Alessandro A, Gazzerro P, et al,. (2012). The CB1 receptor antagonist rimonabant controls cell viability and ascitic tumour growth in mice. Pharmacol Res 65: 365-371.
46. Marshall AD, Lagutina I, Grosveld GC, (2011). PAX3-FOX01 induces cannabinoid receptor 1 to enhance cell invasion and metastasis. Cancer Res 71: 7471-7480.
47. Marsicano G, Lutz B, (1999). Expression of the cannabinoid receptor CB1 in distinct neuronal subpopulations in the adult mouse forebrain. Eur J Neurosci 11: 4213-4225.
48. Martin BR, Mechoulam R, Razdan RK, (1999). Discovery and characterization of endogenous cannabinoids. Life Sci 65: 573-595.
49. Matsuda LA, Lolait SJ, Brownstein MJ, Young AC, Bonner TI, (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
50. Mechoulam R, Hanu L, (2001). The cannabinoids: an overview. Therapeutic implications in vomiting and nausea after cancer chemotherapy, in appetite promotion, in multiple sclerosis, and in neuroprotection. Pain Res Manag 6: 67-73.
51. Mievis S, Blum D, Ledent C, (2011). Worsening of Huntington's disease phenotype in CB1 receptor knockout mice. Neurobiol Dis 42: 524-529.
52. Miller LK, Devi LA, (2011). The highs and lows of cannabinoid receptor expression in disease: mechanisms and their therapeutic implications. Pharmacol Rev 63: 461-470.
53. Mukhopadhyay B, Liu J, Osei-Hyiaman D, Godlewski G, Mukhopadhyay P, Wang L, et al,. (2010). Transcriptional regulation of cannabinoid receptor-1 expression in the liver by retinoic acid acting via retinoic acid receptor-gamma. J Biol Chem 285: 19002-19011.
54. Munro S, Thomas KL, Abu-Shaar M, (1993). Molecular characterization of a peripheral receptor for cannabinoids. Nature 365: 61-65.
55. National Centre for Biotechnology Information (NCBI) (2011). EST Profile Hs.75110-CNR1: cannabinoid receptor 1 (brain). Database of Expressed Sequence Tags (dbEST) EST Profile Viewer. Available at: http://www.ncbi.nlm.nih.gov/ UniGene/ESTProfileViewer.cgi?uglist=Hs.75110.
56. Navarro G, Carriba P, Gandia J, Ciruela F, Casado V, Cortes A, et al,. (2008). Detections of heteromers formed by cannabinoid CB1, dopamine D2, and adenosine A2A G-protein- coupled receptors by combining bimolecular fluorescence complementation and bioluminescence energy transfer. ScientificWorldJournal 11: 1088-1097.
57. Navarro HA, Howard JL, Pollard GT, Carroll FI, (2009). Positive allosteric modulation of the human cannabinoid (CB) receptor by RTI-371, a selective inhibitor of the dopamine transporter. Br J Pharmacol 156: 1178-1184.
58. Nortarnicola M, Messa C, Orlando A, Bifulco M, Laezza C, Gazzerro P, et al,. (2008). Estrogenic induction of cannabinoid CB1 receptor in human colon cancer cell lines. Scand J Gastroenterol 43: 66-72.
59. Pacheco DF, Klein A, Perez AC, Pacheco CM, de Francischi JN, Reis GM, et al,. (2009). Central antinociception induced by mu-opioid receptor agonist morphine, but not delta- or kappa-, is mediated by cannabinoid CB1 receptor. Br J Pharmacol 158: 225-231.
60. Palermo FA, Angelini M, Cottone E, Virgili M, Franzoni MF, Mosconi G, et al,. (2009). Involvement of endocannabinoid CB1 receptor in the modulation of stress responses related to xenoestrogen exposure. Ann N Y Acad Sci 1163: 504-507.
61. Paria BC, Das SK, Dey SK, (1995). The preimplantation mouse embryo is a target for cannabinoind ligand-receptor signalling. Proc Natl Acad Sci U S A 92: 9460-9464.
62. Pazos MR, Sagredo O, Fernandez-Ruiz J, (2008). The endocannabinoid system in Huntington's disease. Curr Pharm Des 14: 2317-2325.
63. Pertwee RG, Howlett AC, Abood ME, Alexander SP, Di Marzo V, Elphick MR, et al,. (2010). International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid receptors and their ligands: beyond CB1 and CB2. Pharmacol Rev 62: 588-631.
64. Pinto JG, Hornby KR, Jones DG, Murphy KM, (2010). Developmental changes in GABAergic mechanisms in human visual cortex across the lifespan. Front Cell Neurosci 4: 1-12.
65. Proto MC, Gazzerro P, Di Croce L, Santoro A, Malfitano AM, Pisanti S, et al,. (2011). Interaction of endocannabinoid system and steroid hormones in the control of colon cancer cell growth. J Cell Physiol 27: 250-258.
66. Rajesh M, Mukhopadhyay P, Haskõ G, Huffman JW, Mackie K, Pacher P, (2008). CB2 cannabinoid receptor agonists attenuate TNF-alpha-induced human vascular smooth muscle cell proliferation and migration. Br J Pharmacol 153: 347-357.
67. Rinaldi-Carmona M, Calandra B, Shire D, Bouaboula M, Oustric D, Barth F, et al,. (1996). Characterization of two cloned human CB1 receptor isoforms. J Pharmacol Exp Ther 278: 871-878.
68. Romero J, Garcia-Palomero E, Berrendero F, Garcia-Gil J, Hernandez ML, Ramos JA, et al,. (1997). Atypical location of cannabinoid receptors in white matter areas during rat brain development. Synapse 26: 317-323.
69. Rozenfeld R, Bushlin I, Gomes I, Tzavaras N, Gupta A, Neves S, et al,. (2012). Receptor heteromerization expands the repertoire of cannabinoid signaling in rodent neurons. PLoS ONE 7: e29239.
70. Ryberg E, Vu HK, Larsson N, Groblewski T, Hjorth S, Elebring T, et al,. (2005). Identification and characterisation of a novel splice variant of the human CB1receptor. FEBS Lett 579: 259-264.
71. Sarzani R, Bordicchia M, Marcucci P, Bedetta S, Santini S, Giovagnoli A, et al,. (2009). Altered pattern of cannabinoid 1 receptor expression in adipose tissue of dysmetabolic and overweight patients. Metabolism 58: 361-367.
72. Shire D, Calandra B, Rinaldi-Carmona M, Oustric D, Pessègue B, Bonnin-Cabanne O, et al,. (1996). Molecular cloning, expression and function of the murine CB2 peripheral cannabinoid receptor. Biochim Biophys Acta 1307: 132-136.
73. Silverdale MA, McGuire S, McInnes A, Crossman AR, Brotchie JM, (2001). Striatal cannabinoid CB1 receptor mRNA expression is decreased in the reserpine-treated rat model of Parkinson's disease. Exp Neurol 169: 400-406.
74. Smith TH, Sim-Selley LJ, Selley DE, (2010). Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery? Br J Pharmacol 160: 454-466.
75. Steiner H, Bonner TI, Zimmer AM, Kitai ST, Zimmer A, (1999). Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc Natl Acad Sci U S A 96: 5786-5790.
76. Straiker A, Wagner-Miller J, Hutchens J, Mackie K, (2012). Differential signaling in human cannabinoid CB1 receptors and their splice variants in autaptic hippocampal neurons. Br J Pharmacol 165: 2660-2671.
77. Thrash B, Thiruchelvan K, Ahuja M, Suppiramaniam V, Dhanasekaran M, (2009). Methampethamine-induced neurotoxicity: the road to Parkinson's disease. Pharmacol Rep 61: 966-977.
78. Uriguen L, Garcia-Fuster MJ, Callado LF, Morentin B, La Harpe R, Cassado V, et al,. (2009). Immunodensity and mRNA expression of A2Aadenosine, D2 dopamine, and CB1 cannabinoid receptors in post-mortem frontal cortex of subjects with schizophrenia: effect of antipsychotic treatment. Psychopharmacology (Berl) 206: 313-324.
79. Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB, et al,. (2005). Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signalling in the prefrontal cortex of alcoholic suicide victims. Biol Psychiatry 57: 480-486.
80. Vitalis T, Laine J, Simon A, Roland A, Leterrier C, Lenkei Z, (2008). The type 1 cannabinoid receptor is highly expressed in embryonic cortical projection neurons and negatively regulates neurite growth in vitro. Eur J Neurosci 28: 1705-1718.
81. Wang D, Wang H, Ning W, Backlund MG, Dey SK, DuBois RN, (2008). Loss of cannabinoid receptor 1 accelerates intestinal tumor growth. Cancer Res 68: 6468-6476.
82. Westlake TM, Howlett AC, Bonner TI, Matsuda LA, Herkenham M, (1994). Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience 63: 637-652.
83. Xiao JC, Jewell JP, Lin LS, Hagmann WK, Fong TM, Shen CP, (2008). Similar in vitro pharmacology of human cannabinoid CB1 receptor variants expressed in CHO cells. Brain Res 1238: 36-43.
84. Zeng BY, Dass B, Owen A, Rose S, Cannizzaro C, Tel BC, et al,. (1999). Chronic L-DOPA treatment increases striatal cannabinoid CB1 receptor mRNA expression in 6-hydroxydopamine-lesioned rats. Neurosci Lett 276: 71-74.
85. Zhang F, Hong S, Stone V, Smith PJ, (2007). Expression of cannabinoid CB1 receptors in models of diabetic neuropathy. J Pharmacol Exp Ther 323: 508-515.
86. Zhang P-W, Ishiguro H, Ohtsuki T, Hess J, Carillo F, Walther D, et al,. (2004). Human cannabinoid receptor 1: 5' exons, candidate regulatory regions, polymorphisms, haplotypes and association with polysubstance abuse. Mol Psychiatry 9: 916-931.
87. Zhuang S, Kittler J, Grigorenko EV, Kirby MT, Sim LJ, Hampson RE, (1998). Effects of long- term exposure to delta9-THC on expression of cannabinoid receptor (CB1) mRNA in different rat brain regions. Brain Res Mol Brain Res 62: 141-149.
88. Zimmer A, Zimmer AM, Hohmann AG, Herkenham M, Bonner TI, (1999). Increased motality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice. Proc Natl Acad Sci U S A 96: 5780-5785.
89. Zurolo E, Iyer AM, Spliet WG, Van Rijen PC, Troost D, Gorter JA, et al,. (2010). CB1 and CB2 cannabinoid receptor expression during development and in epileptogenic development pathologies. Neuroscience 170: 28-41.